ProPhase Labs Statistics
Total Valuation
ProPhase Labs has a market cap or net worth of $32.72 million. The enterprise value is $62.05 million.
Important Dates
The next estimated earnings date is Friday, November 15, 2024, before market open.
| Earnings Date | Nov 15, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
ProPhase Labs has 19.08 million shares outstanding. The number of shares has increased by 9.49% in one year.
| Current Share Class | 19.08M |
| Shares Outstanding | 19.08M |
| Shares Change (YoY) | +9.49% |
| Shares Change (QoQ) | +4.67% |
| Owned by Insiders (%) | 17.47% |
| Owned by Institutions (%) | 9.52% |
| Float | 15.75M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.95 |
| Forward PS | 0.32 |
| PB Ratio | 0.84 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.45 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.58, with a Debt / Equity ratio of 0.61.
| Current Ratio | 1.58 |
| Quick Ratio | 1.24 |
| Debt / Equity | 0.61 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -17.62 |
Financial Efficiency
Return on equity (ROE) is -50.92% and return on invested capital (ROIC) is -28.94%.
| Return on Equity (ROE) | -50.92% |
| Return on Assets (ROA) | -22.98% |
| Return on Capital (ROIC) | -28.94% |
| Revenue Per Employee | $159,044 |
| Profits Per Employee | -$232,832 |
| Employee Count | 113 |
| Asset Turnover | 0.19 |
| Inventory Turnover | 5.24 |
Taxes
| Income Tax | -9.41M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -62.45% in the last 52 weeks. The beta is -0.10, so ProPhase Labs's price volatility has been lower than the market average.
| Beta (5Y) | -0.10 |
| 52-Week Price Change | -62.45% |
| 50-Day Moving Average | 2.38 |
| 200-Day Moving Average | 4.02 |
| Relative Strength Index (RSI) | 27.31 |
| Average Volume (20 Days) | 29,095 |
Short Selling Information
The latest short interest is 206,120, so 1.08% of the outstanding shares have been sold short.
| Short Interest | 206,120 |
| Short Previous Month | 231,008 |
| Short % of Shares Out | 1.08% |
| Short % of Float | 1.31% |
| Short Ratio (days to cover) | 7.69 |
Income Statement
In the last 12 months, ProPhase Labs had revenue of $17.97 million and -$26.31 million in losses. Loss per share was -$1.46.
| Revenue | 17.97M |
| Gross Profit | -1.64M |
| Operating Income | -33.96M |
| Pretax Income | -32.20M |
| Net Income | -26.31M |
| EBITDA | -27.01M |
| EBIT | -33.96M |
| Loss Per Share | -$1.46 |
Full Income StatementBalance Sheet
The company has $1.78 million in cash and $26.82 million in debt, giving a net cash position of -$25.04 million or -$1.31 per share.
| Cash & Cash Equivalents | 1.78M |
| Total Debt | 26.82M |
| Net Cash | -25.04M |
| Net Cash Per Share | -$1.31 |
| Equity (Book Value) | 44.08M |
| Book Value Per Share | 2.31 |
| Working Capital | 16.13M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$14.80 million and capital expenditures -$2.94 million, giving a free cash flow of -$17.75 million.
| Operating Cash Flow | -14.80M |
| Capital Expenditures | -2.94M |
| Free Cash Flow | -17.75M |
| FCF Per Share | -$0.93 |
Full Cash Flow StatementMargins
Gross margin is -9.11%, with operating and profit margins of -188.93% and -146.39%.
| Gross Margin | -9.11% |
| Operating Margin | -188.93% |
| Pretax Margin | -198.76% |
| Profit Margin | -146.39% |
| EBITDA Margin | -150.31% |
| EBIT Margin | -188.93% |
| FCF Margin | -71.30% |
Dividends & Yields
ProPhase Labs does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -9.49% |
| Shareholder Yield | -9.49% |
| Earnings Yield | -76.40% |
| FCF Yield | -51.54% |
Dividend DetailsAnalyst Forecast
The average price target for ProPhase Labs is $11.00, which is 541.40% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $11.00 |
| Price Target Difference | 541.40% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on January 23, 1997. It was a forward split with a ratio of 2:1.
| Last Split Date | Jan 23, 1997 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
ProPhase Labs has an Altman Z-Score of 0.05 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.05 |
| Piotroski F-Score | 1 |